replimune.com (REPL): Price-to-Projected Revenue Ratio

REPL (Replimune Group Inc) - company brandmark

Replimune Group, Inc. (REPL) relies on external contractors for production and testing, which heightens risks due to its narrow specialization in a single product. The forward P/S indicator captures the dynamics of the market's revenue valuation, where the mark reflects the latest data. Meanwhile, the company strictly adheres to biosafety and ethical standards during immunotherapy development, minimizing hazardous waste.

REPL Replimune Group Inc: Market Cap to Future Revenue Ratio in the range 07/04/2022 - 11/13/2026

Analytical breakdowns for Replimune Inc. (REPL)

- stock price and consensus target price:
Stock Quotes Replimune|REPL - Analyst Consensus Forecast
- stock exchange capitalization data:
Market Value Replimune Inc.|REPL - Business Value
- book value of equity indicators:
Net Assets per Single Share Replimune|REPL - Total Stockholders' Equity|Market Cap to Net Assets Ratio replimune.com|REPL - Company Balance Sheet Assets
- company total debt and liquidity indicators:
Total Debt to Equity Ratio Replimune Group, Inc.|REPL - Long-Term Loans to Capital Ratio|Short-Term Debt to Capital Replimune Group, Inc.|REPL - Aggregate Debt Obligations|Debts to Book Capitalization Replimune Inc.|REPL - Long-Term Debt|Company Short-Term Debt Replimune|Quick Ratio replimune.com
- business earnings and investment ratios data:
REPL - Net Profit|Expected Profit Replimune Group, Inc.|REPL - Market Cap to Net Income|Projected Price to Earnings Replimune Corp|REPL - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Replimune Inc.|REPL - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Replimune|REPL - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months replimune.com|REPL - Earnings per share trend in current year|Net earnings per share growth forecast for next year Replimune Group, Inc.
- revenue and sales details:
REPL - Company Revenue|Projected Sales Volume Replimune|REPL - Price-to-Revenue Coefficient|Price-to-Projected Revenue Ratio Replimune Inc.
Summary company analysis:Replimune REPL
Manufactured products of Replimune Inc.

Forward P/S measures the market value of a company relative to expected sales volume, allowing investors to assess the fundamental margin of safety and capitalization dynamics between quarterly reports. Analysis of the forward P/S metric confirms the efficiency of the asset-light business model of Replimune Group, Inc. (REPL), where the absence of capital expenditures on manufacturing plants shifts the valuation focus from assets to future revenue potential.

Competitor analysis

ImmunityBio - Forward Price-to-Revenue Multiple|Forward P/S Multiple Immunocore Holdings IMCR|JANX - Price-to-Projected Revenue Ratio|RCUS (Arcus Corp) - Market Cap to Projected Revenue|Zymeworks Inc. (ZYME) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio tangotx.com (TNGX)|Forward Price-to-Revenue Multiple IOVA|IMTX - Projected Price to Revenue|Forward Price-to-Revenue Multiple XNCR (Xencor Corp)|Price to Expected Revenue Ratio CMPX|Forward P/S Multiple LYEL (Lyell Immunopharma)|Forward Price to Sales IPHA|Pyxis - Forward P/S Multiple|Market Cap to Future Revenue Ratio Compugen Ltd.|IO Biotech Corp (IOBT) - Price-to-Projected Revenue Ratio|Sutro Biopharma, Inc - Forward Price to Sales|INKT (MiNK Therapeutics, Inc.) - Forward P/S Multiple|Forward P/S Multiple Werewolf|Price-to-Projected Revenue Ratio Immix Biopharma, Inc. (IMMX)|ALXO: Future Price to Revenue|Cue Biopharma, Inc. - Forward Price-to-Revenue Multiple|PDS Biotech (PDSB) - Market Cap to Future Revenue Ratio|SONN - Price-to-Projected Revenue Ratio|Forward Price to Sales MAIA (MAIABiotech.com)|LIMN: Forward P/S Multiple|Market Cap to Future Revenue Ratio LAVA Therapeutics (LVTX)|Price-to-Projected Revenue Ratio NextCure Corp|Leap Tx - Future Price to Revenue|Price-to-Projected Revenue Ratio Intensity Therapeutics (INTS)|Price-to-Projected Revenue Ratio SNSE (senseibio.com)|Forward P/S Multiple TOVX (Theriva Biologics)|Market Cap to Expected Sales Ratio Gritstone bio Inc. (GRTS)|KA - Price-to-Projected Revenue Ratio|NexImmune Corporation (NEXI) - Forward Price-to-Revenue Multiple|TSBX (turnstonebio.com) - Forward Price-to-Revenue Multiple|vaccinex.com (VCNX) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Harpoon Therapeutics, Inc.